Full-spectrum cannabis oil given go-ahead for clinical trial in search of treatment for neuropsychiatric disorders in children.
Neurotech International has been given the go-ahead to launch a phase I/II clinical trial in Australia of its NTI164 cannabinoid-based drug formulation in children with PANDAS and PANS.
Neurotech International has been given the go-ahead to launch a phase I/II clinical trial in Australia of its NTI164 cannabinoid-based drug formulation in children with PANDAS and PANS.
Source: Cannabiz